Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Article | IMSEAR | ID: sea-185533

ABSTRACT

Teratoma constitutes 20% of all ovarian neoplasms .The origin of teratomas has been a matter of interest, speculation, and dispute for centuries. OBJECTIVE:The aim of the study is to characterize the clinical and detailed histopathological features of ovarian teratomas.. METHODS: The study was a cross sectional observational study carried out in a tertiary care teaching hospital, Kolkata. The specimens labelled as ovarian tumours were subjected for detailed histopathological examinations with clinical features noted. RESULTS: Out of total 50 cases of ovarian teratomas, 46(92%) were mature cystic teratoma (MCT). The mean age of occurrence is 31.5 years, mostly (64%) presented with pain abdomen. Unilateral (98%) presentation with right ovarian involvement (70%) was noted. Squamous cell Ca is the most common malignant transformation. CONCLUSION: Good grossing and detailed characterisation of histopathology have immense value to choose proper therapeutic approach.

2.
Article in English | IMSEAR | ID: sea-147779

ABSTRACT

Background & objectives: Current therapy for leishmaniasis is limited and unsatisfactory. Amphotericin B, a second-line treatment is gradually replacing antimonials, the first-line treatment and is used as the preferred treatments in some regions. Though, presently it is the only drug with highest cure rate, its use is severely restricted by its acute toxicity. In the present study novel lipid-amphotericin B formulations with lower toxicity than the parent drug were evaluated for the treatment of visceral leishmaniasis (VL) in a mouse model. Methods: The toxicity and therapeutic efficacy of a new amphiphilic formulation of amphotericin B (KalsomeTM10) was compared to that of amphotericin B deoxycholate (Fungizone) in a mouse model of VL using quantitative real-time PCR (qRT-PCR). Results: The toxicity of amphotericin B was significantly less with liposomal formulation as compared to the deoxycholate form, evidenced by reduced nephrotoxicity and higher tolerated dose in BALB/c mice. The therapeutic efficacy was evaluated by quantitative real time (RT) PCR using primers highly specific for the ITS region of Leishmania donovani. There was reduction in parasite load by 2 log unit after 7 days of treatment and finally resulting in complete clearance of parasite from infected mice after 30 days of treatment with KalsomeTM10. Interpretation & conclusions: This new formulation showed a favourable safety profile and better efficacy when compared to conventional amphotericin B. If production cost is kept low, it may prove to be a feasible alternative to conventional amphotericin B.

SELECTION OF CITATIONS
SEARCH DETAIL